Dermata Therapeutics Statistics
Total Valuation
DRMA has a market cap or net worth of $2.55 million. The enterprise value is -$3.55 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
Earnings Date | Nov 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
DRMA has 2.04 million shares outstanding. The number of shares has increased by 486.90% in one year.
Current Share Class | 2.04M |
Shares Outstanding | 2.04M |
Shares Change (YoY) | +486.90% |
Shares Change (QoQ) | +129.79% |
Owned by Insiders (%) | 0.71% |
Owned by Institutions (%) | 0.36% |
Float | 1.84M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.45 |
P/TBV Ratio | 0.55 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.44
Current Ratio | 3.44 |
Quick Ratio | 3.16 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -202.20% and return on invested capital (ROIC) is -129.32%.
Return on Equity (ROE) | -202.20% |
Return on Assets (ROA) | -102.89% |
Return on Capital (ROIC) | -129.32% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.41M |
Employee Count | 8 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
DRMA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -486.90% |
Shareholder Yield | -486.90% |
Earnings Yield | -434.86% |
FCF Yield | -362.56% |
Analyst Forecast
The average price target for DRMA is $6.00, which is 379.69% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $6.00 |
Price Target Difference | 379.69% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on May 16, 2024. It was a reverse split with a ratio of 0.0666667:1.
Last Split Date | May 16, 2024 |
Split Type | Reverse |
Split Ratio | 0.0666667:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |